Daron Evans News Today

Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) was the recipient of a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 814,600 shares, a growth of 162.0% from the May 15th total of 310,900 shares. Based on an average daily trading volume, of 571,100 shares, […]

HC Wainwright restated their buy rating on shares of Rezolute (NASDAQ:RZLT – Free Report) in a research note released on Thursday, Benzinga reports. They currently have a $14.00 price target on the stock. A number of other analysts have also recently weighed in on the stock. JMP Securities reissued a market outperform rating and set […]

JMP Securities reaffirmed their market outperform rating on shares of Rezolute (NASDAQ:RZLT – Free Report) in a research report released on Thursday, Benzinga reports. They currently have a $7.00 price target on the stock. RZLT has been the subject of several other reports. HC Wainwright reiterated a buy rating and set a $14.00 target price […]

The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) CFO Daron Evans purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was bought at an average cost of $1.93 per share, with a total value of $96,500.00. Following the completion of the purchase, the chief financial officer now […]

13.02.2024 - Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access ...

REDWOOD CITY, Calif., Jan. 24, 2024 -- Rezolute, Inc. , a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare...

Operator: Good day, and welcome to the Envelope Enterprise Holdings Second Half and Fiscal Year 2022 Earnings Conference Call. Please note, this event is being recorded.